

20 January 2021



2021 Cystic Fibrosis Innovation Grant

partnering with 4DMedical

Cystic Fibrosis Australia (CFA) is pleased to announce a new addition to the 2021 Innovation Grant for post-doctoral researchers, currently working in cystic fibrosis (CF) research.

This year's Innovation Grant will continue to focus on respiratory research but now provide the opportunity to incorporate non-invasive, functional lung imaging provided by 4DMedical.

There is a clinical need to develop measures that accurately reflect treatment effects and sensitively to detect mild CF lung disease. And 4DMedical has agreed to make their imaging technology software - **XV LVAS** (XV Technology Lung Ventilation Analysis Software) – available to all researcher establishments.

The 4DMedical Innovation Grant will allow a CF researcher to explore novel respiratory research concepts at the initial feasibility stage and to incorporate 4DMedical's non-invasive functional lung imaging technology – **XV LVAS**.

Innovation Grant applications relating to any aspect in the field of CF are encouraged, even those lacking pilot data. The grant aims to allow the researcher to generate sufficient data within the one-year grant period to be in a position to apply for additional support from an appropriate funding body to continue the research.

The Innovation Grant will be offered to post-doctoral researchers currently working in or proposing to work in CF research. The researcher will have completed a research higher degree in CF or a related area within the last ten years.

The recipient of the Innovation Grant is required to provide progress reports on their research to CFA every six months. In addition, and where appropriate, the recipient will be asked to make a presentation at a CFA conference (held every two years) in Australia.

The maximum amount awarded under the 4DMedical Innovation Grant will be \$80,000. The actual amount provided will be subject to approval of the applicant's budget. This grant is awarded annually to one applicant for one year.

4DMedical's functional clinical lung imaging - **XV LVAS** - will be provided free of charge to the winner of the 2021 Innovation Grant and other Grant applicants.

Applications can be made [HERE](#) through the website of The Thoracic Society of Australia & New Zealand (TSANZ) and must be received by TSANZ by 5.00 pm AEDT on 12th February 2021.

This deadline extension is to enable researchers to incorporate the use of 4DMedical's non-invasive functional lung imaging technology – **XV LVAS** in their application.

For more information about the 4DMedical Innovation Grant email nickim@cfa.org.au. For more details about non-invasive functional lung imaging and 4DMedical's commitment to Australia go to www.cysticfibrosis.org.au/who-we-are/our-partners or www.4DMedical.com <https://vimeo.com/468393874>

Kind regards

A handwritten signature in black ink that reads "Nettie Burke". The signature is written in a cursive, flowing style.

Nettie Burke, CEO
Cystic Fibrosis Australia
nettieb@cfa.org.au